Trovagene is a clinical-stage, oncology therapeutics company, taking a precision medicine approach and integrating a biomarker strategy to develop targeted drugs to treat leukemias, lymphomas and solid tumor cancers. Our drug candidate, onvansertib, is a first-in-class, 3rd generation Polo-like Kinase Inhibitor with best-in-class attributes. Onvansertib is highly-selective for PLK1, which is over-expressed in most cancers; it is orally administered; synergistic in combination with numerous chemotherapies and targeted therapeutics; has a half-life of 24-hours which allows for flexibility in dosing and schedule. We are developing onvansertib as part of combination regimens with already approved drugs for the treatment of cancers and indications where there is a significant medical need for new treatment options. Source
No articles found.
Neuralstem is a biopharmaceutical company developing novel treatments for nervous ...
Neuralstem is a biopharmaceutical company devel...
Guardion Health Sciences is at the forefront of early detection, intervention and ...
Guardion Health Sciences is at the forefront of...
Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on devel...
Jaguar Health, Inc. is a commercial stage pharm...
We are a clinical-stage biopharmaceutical company focused on significantly improvi...
We are a clinical-stage biopharmaceutical compa...
resTORbio, Inc. is a clinical-stage biopharmaceutical company developing innovativ...
resTORbio, Inc. is a clinical-stage biopharmace...
Soleno Therapeutics, Inc. (Soleno) is focused on the development and commercializa...
Soleno Therapeutics, Inc. (Soleno) is focused o...
UroGen Pharma Ltd. is a clinical-stage biopharmaceutical company developing advanc...
UroGen Pharma Ltd. is a clinical-stage biopharm...
Join the National Investor Network and get the latest information with your interests in mind.